GlassScriptPhysician profile
Keith B Johnson
NPI 1184695710
$18,946.11
in general payments reported to CMS, 2019-2025
67 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,472 · 2020: $2,863 · 2021: $3,277 · 2022: $2,837 · 2023: $1,905 · 2024: $2,269 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,496.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,124.06 | 2019-2025 | |
| Amgen INC. | $1,962.44 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $1,505.13 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,409.93 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $1,095.92 | 2019-2025 | |
| Glaxosmithkline, LLC. | $801.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $755.79 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Allergan, INC. | $570.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $536.40 | 2019-2024 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $516.64 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $494.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $450.25 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $405.43 | 2019-2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $385.98 | 2020-2021 | |
| Boston Scientific Corporation | $358.02 | 2019-2025 | Watchman Flx, Watchman Access System, Superion Indirect Decompression System |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $347.54 | 2019-2025 | Tymlos |
| Astellas Pharma US INC | $321.85 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $311.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Cleerly, INC. | $287.90 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Biohaven Pharmaceutical Holding Company LTD. | $283.65 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $272.06 | 2019-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $267.25 | 2019-2023 | |
| Dexcom, INC. | $262.41 | 2021-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $251.45 | 2019-2024 | Contrave, Onzetra Xsail |
| Melinta Therapeutics, LLC | $248.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $240.29 | 2019-2025 | |
| Tris Pharma INC | $237.37 | 2020-2025 | Onyda Xr |
| Amarin Pharma, INC. | $230.61 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $199.22 | 2025 | Caplyta |
| Assertio Therapeutics, INC. | $134.18 | 2019-2020 | |
| Corium, LLC | $122.35 | 2023-2025 | Azstarys |
| Abbott Laboratories | $114.12 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.06 | 2020-2022 | |
| Almatica Pharma LLC | $104.64 | 2021-2023 | Gralise, Sertraline Hcl, Loreev Xr |
| Collegium Pharmaceutical, INC. | $90.89 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $80.30 | 2019 | |
| Eisai INC. | $69.71 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $66.70 | 2023-2025 | Qelbree, Qelbree |
| Paratek Pharmaceuticals, INC. | $64.39 | 2022-2024 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $56.93 | 2019-2023 | Evkeeza |
| Ironshore Pharmaceuticals INC. | $56.38 | 2019-2024 | |
| Shire North American Group INC | $55.05 | 2019 | |
| Axsome Therapeutics, INC. | $46.12 | 2025 | Auvelity |
| Vivus LLC | $45.57 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $42.28 | 2023-2024 | Quviviq |
| Genentech USA, INC. | $42.24 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $38.69 | 2019 | |
| Avanir Pharmaceuticals, INC. | $37.27 | 2019 | |
| Duchesnay USA Incorporated | $35.20 | 2019 | |
| Exeltis, USA INC. | $33.11 | 2024-2025 | Slynd |
| Teva Pharmaceuticals USA, INC. | $31.50 | 2021 | |
| Alk-Abello, INC | $30.22 | 2023 | Grastek, Odactra, Ragwitek |
| Phathom Pharmaceuticals, INC. | $29.05 | 2024-2025 | Voquezna |
| Centinel Spine, LLC | $28.00 | 2021 | |
| Insulet Corporation | $24.63 | 2025 | Omnipod |
| Therapeuticsmd, INC. | $23.47 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.86 | 2024 | Ycanth |
| Mylan Specialty L.P. | $22.40 | 2022 | |
| Irhythm Technologies, INC. | $21.78 | 2022 | |
| Baxter Healthcare | $20.91 | 2024 | Hillrom - Monarch Airway Clearance System |
| Phadia US INC. | $19.44 | 2025 | Immunocap |
| Rhodes Pharmaceuticals L.P. | $17.98 | 2019 | |
| Sequel Med Tech, LLC | $17.55 | 2025 | Twiist |
| Inspire Medical Systems, INC. | $17.06 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $17.04 | 2019 | |
| Aytu Biopharma, INC. | $16.49 | 2019 | |
| Adlon Therapeutics L.P. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.